Neoplasia hematologikoak: Leuzemiak, Linfomak eta Mielomak

MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME

Resumen de: US20260092097A1

The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA

Resumen de: AU2024390850A1

Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.

METHODS FOR TREATING MULTIPLE MYELOMA COMPRISING AN ANTI-CD38 ANTIBODY COMBINED WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE

Resumen de: AU2024360739A1

The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

SOS1 INHIBITORS FOR USE IN THE TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE BLOOD CANCERS

Resumen de: AU2024341370A1

The present disclosure provides SOS-1 inhibitors, such as bicyclic compounds or macrocyclic compounds, alone or in combination with TKI - resitant to BCR-ABL tyrosine kinase, such as dasatinib or imatinib, for use in the treatment of philadelphia chromosome positive (Ph+) blood cancer, such as CML (chronic myelogenous leukemia, also named chronic myeloid leukemia), Ph+ALL (acute lymphoblastic leukemia) and Ph+AML (acute lymphoblastic lymphoma).

SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY

Resumen de: US20260092085A1

A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA/RNA/PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Resumen de: US20260085082A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

METHODS OF REDUCING THE RISK OF DEVELOPING HEMATOLOGIC MALIGNANCIES

Resumen de: WO2026060534A1

Disclosed are methods of reducing the risk of a subject developing hematologic malignancies and myelodysplastic syndrome, the methods comprising administering an effective amount of colchicine to the subject, wherein the subject has been determined to have a clonal hematopoiesis mutation.

BIOMARKER FOR MULTIPLE MYELOMA

Resumen de: WO2026063424A1

The present invention provides a method and the like for predicting prognosis of multiple myeloma using, as a novel biomarker, IL5RA of extracellular vesicles derived from a biological sample of a subject.

COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME WITH GLYCINE TRANSPORT INHIBITORS

Resumen de: WO2026064696A1

The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating MDS, and related syndromes/conditions/symptoms thereof.

PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY

Resumen de: US20260085073A1

The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein I (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.

DOWNREGULATING INOS TO INCREASE CAR-T KILLING

Resumen de: US20260083844A1

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.

ANTI-CD123 IMMUNOCONJUGATES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Resumen de: US20260083749A1

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.

TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA

Resumen de: US20260083707A1

There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF

Resumen de: US20260085064A1

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structuralor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

OIL-IN-WATER EMULSIONS FOR TOPICAL ADMINISTRATION AND USES THEREOF

Resumen de: US20260083673A1

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

ANTIBODY BINDING LILRB4 AND CD3, AND USE THEREOF

Resumen de: EP4714975A1

The present disclosure provides an antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. The present disclosure also relates to a method for treating a solid tumor, multiple myeloma, or leukemia such as acute myeloid leukemia (AML) using the anti-LILRB4×CD3 bispecific antibody of the present disclosure.

NOVEL POLYPEPTIDE, POLYPEPTIDE DERIVATIVE AND USE THEREOF

Resumen de: AU2024321283A1

Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and/or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.

MULTIPLE MYELOMA MICROORGANOSPHERES

Resumen de: US20260078348A1

MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.

INHIBITORS OF ENL/AF9 YEATS AND FLT3

Resumen de: US20260078121A1

Compounds and pharmaceutical compositions comprising compounds that inhibit ENL/AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and pharmaceutical compositions comprising the compounds are also disclosed. The compounds, pharmaceutical compositions and methods can be used to inhibit key drivers of cancer and cancer stem cell survival.

COMPOSITIONS COMPRISING PRALATREXATE FOR SUBCUTANEOUS ADMINISTRATION AND METHODS OF USE THEREOF

Resumen de: AU2024341403A1

The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of disease (e.g., lymphoma).

METHODS AND MATERIALS FOR TARGETING C-C CHEMOKINE RECEPTOR-LIKE 2 (CCRL2)

Resumen de: WO2026060097A1

This document provides methods and materials for targeting C-C chemokine receptor-like 2 (CCRL2) in a subject (e.g., a mammal). For example, methods and materials provided herein can be used to treat a condition that involves the overexpression of CCRL2 such as, without limitation, a cancer (e.g., myelodysplastic syndrome or acute myeloid leukemia) or tuberculosis. Treatment can include administering an anti-CCRL2 antibody, an antibody-drug conjugate, a chimeric antigen receptor T cell, or combinations thereof.

METHODS OF TREATING MULTIPLE MYELOMA WITH BCMA INHIBITORS IN COMBINATION WITH LAG3 INHIBITORS

Resumen de: WO2026059921A1

The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with a LAG3 inhibitor (e.g., an anti-LAG3 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.

HUMANIZED ANTIBODY TARGETING HUMAN CD33 AND USE THEREOF

Resumen de: WO2026056681A1

Provided are a monoclonal antibody targeting human CD33 and a humanized antibody thereof, and also provided are a composition comprising the antibody, a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate, which facilitate prediction, diagnosis and treatment monitoring of related diseases such as myeloid leukemia.

RNA HELICASE INHIBITOR

Resumen de: AU2024328882A1

There is provided A compound of formula I, a salt or solvate thereof as described herein, for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative disorders, colorectal cancer, medulloblastoma, renal, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous cancer, gastrointestinal stromal tumor, glioma, myxofibrosarcoma, leiomyosarcoma, neuroblastoma, synovial sarcoma, mesothelioma, gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer, and neural cancer.

THERAPEUTIC COMBINATIONS OF AN AKT INHIBITOR, A BCL-2 INHIBITOR, AND A GLUCOCORTICOID

Nº publicación: WO2026057582A1 19/03/2026

Solicitante:

ASTRAZENECA AB [SE]
ASTRAZENECA AB

Resumen de: WO2026057582A1

Therapeutic combinations of an AKT inhibitor and a BCL-2 inhibitor; an AKT inhibitor and a glucocorticoid; and an AKT inhibitor, a BCL-2 inhibitor and a glucocorticoid are described. The combinations can be useful in the treatment of acute lymphoblastic leukemia (ALL).